Share Facebook Twitter LinkedIn Pinterest Email Newmark targets $630M adjusted EBITDA by 2026 amid growth in market share and business lines
AngioDynamics signals FY2026 adjusted EBITDA of $10M-$12M while raising net sales guidance to $313.5M-$315.5M (NASDAQ:ANGO)April 2, 2026